Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic-Reference-Cited by-同舟云学术

Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic

Published:2024-01 Issue:1 Volume:26 Page:73-84
ISSN:1525-1578
Container-title:The Journal of Molecular Diagnostics
language:en
Short-container-title:The Journal of Molecular Diagnostics

Author:

Gray Jhanelle E.,Han Ji-Youn^ORCID,Telaranta-Keerie Aino,Huang Xiangning,Kohlmann Alexander,Hodge Rachel,Rukazenkov Yuri,Chmielecki Juliann,Espenschied Carin R.^ORCID,Lefterova Martina,Wu Yi-Long,Ramalingam Suresh S.,Barrett J. Carl,Odegaard Justin I.

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Molecular Medicine,Pathology and Forensic Medicine

Reference50 articles.

1. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

2. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer;Peters;N Engl J Med,2017

3. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1);Drilon;Cancer Discov,2017

4. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial;Planchard;Lancet Oncol,2017

5. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials;Doebele;Lancet Oncol,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer;Cancers;2024-06-12

2. Emerging role of liquid biopsies and advanced imaging in early detection and monitoring of oral oncology;Oral Oncology Reports;2024-06